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Introduction
Sickle-cell anaemia (SCA) is one of the most commonly inherited disorders and is associated with both unpredictable recurrent acute pain and chronic pain. 1 Opioids, specifically morphine has been the drug of choice for the treatment of severe pain associated with SCA. 1, 2 Morphine is highly histaminergic, and is known to activate mast cells. 2 We showed earlier that mast cells contribute to neurogenic inflammation and hyperalgesia in sickle mice. 3 We also found that cannabinoids ameliorate chronic and hypoxia/reoxygenation-evoked acute hyperalgesia in sickle mice. 4, 5 Cannabinoids have anti-inflammatory effects and provide protection from ischemia/reperfusion injury. [6] [7] [8] [9] [10] Since pain is a manifestation of complex sickle pathobiology including inflammation, vascular dysfunction and ischemia reperfusion injury, we sought to examine cannabinoid receptor-specific modulation of vascular function, inflammation and hyperalgesia.
Cannabinoid receptors (CBRs), CB1R and CB2R are expressed in the central nervous system (CNS) and non-CNS tissues, including inflammatory cells. [11] [12] [13] [14] [15] CB1R and CB2R 
Pain-related behaviors
Mice were acclimatized to each test protocol in a quiet room at constant temperature and tested for thermal-(heat and cold), mechanical-, and deep tissue-hyperalgesia (grip force), and catalepsy (bar test). 4 
Hyoxia/Reoxygenation
Mice were exposed to hypoxia with 8% O 2 and 92% N 2 for 3h followed by reoxygenation at room air for 1h. Table S1 . A p-value of < 0.05 was considered significant. All data are presented as mean ± SEM.
Results

Cannabinoids ameliorate chronic hyperalgesia in sickle mice
Similar to chronic pain in SCA, HbSS-BERK sickle mice demonstrate tonic hyperalgesia 4, 5, 20 compared to HbAA-BERK control mice and hypoxia/reoxygenation evoked acute hyperalgesia simulating VOC pain. 5 Earlier we showed that a single injection of CP55,940, a non-selective cannabinoid receptor agonist, at a dose of 0.3 mg/Kg ameliorated tonic deep tissue as well as CFA-induced mechanical hyperalgesia in these sickle mice. 4 Chronic pain requires repeated treatment, which can result in tolerance, Figure 2 ). However, the CB2R agonist was only able to decrease the deep tissue hyperalgesia significantly following 7 days of treatment (P<0.05 Vs baseline or vehicle; Figure 2A ). CB2R agonist did not show a significant effect on mechanical and thermal (heat and cold) hyperalgesia (Figure 2 B-D). Therefore, under normoxic conditions representative of chronic pain in SCA, CB1R agonist as well as non-selective CBR agonist CP55,940 appear to be uniformly effective in attenuating different pain phenotypes including deep tissue, mechanical and thermal hyperalgesia in sickle mice.
Cannabinoids ameliorate hyperalgesia via cannabinoid receptors
On the other hand, CB2R agonist only ameliorated deep tissue hyperalgesia, suggesting that CB1R agonism is critical for treating phenotypically diverse chronic pain in SCA.
Earlier we found that H/R-evoked acute deep tissue hyperalgesia in sickle mice was ameliorated by a single injection of CP55,940. 4 Here we examined if treatment with cananbinoids would prevent HR-evoked hyperalgesia. Pre-treatment of mice with CP55,940, and CB1R agonist for 7 days decreased tonic hyperalgesia and also prevented HR-evoked deep tissue, mechanical and thermal hyperalgesia ( Furthermore, to determine the contribution of either CB1R or CB2R to the analgesia provided by CP55,940, we treated CB2R deleted (HbSS CB2R -/-) and intact CB2R
(HbSS CB2R +/+ ) sickle mice with a single dose of CP55,940 under normoxia ( Figure 3 ).
Control CB2R -/-and sickle CB2R -/-mice did not differ in the baseline hyperalgesia as compared to control CB2R +/+ and sickle CB2R +/+ , respectively. An increase in grip force was observed in control CB2R +/+ mice following CP55,940 treatment, but not in control CB2R -/-mice ( Figure 3A ). CP55,940 had no effect on mechanical or cold sensitivity in control CB2R -/-mice and CB2R +/+ ( Figure 3B, D) . Conversely, CP55,940 increased heat sensitivity in control CB2R -/-mice but had no effect on control CB2R +/+ ( Figure 3C ).
CP55,940 treatment did not lead to catalepsy since the bar test ( Figure 3E ) did not show a significant difference from baseline in any group.
Sickle CB2R -/-and sickle CB2R +/+ displayed similar pain behaviors at baseline and a significant decrease in hyperalgesia following CP55,940 treatment ( Figure 3 A-D).
However, significantly higher improvement in heat (p < 0.001) and deep tissue hyperalgesia (p < 0.01), was observed in sickle CB2R -/-compared to sickle CB2R +/+ following CP55,940 treatment. Therefore, different pain phenotypes may utilize CB1R or CB2R to a variable extent to respond to cannabinoid therapy. Together, these data suggest that under both chronic and acute pain condition, activation of CB1R is critical to ameliorate hyperalgesia, and CB2R may partly contribute to cananbinoid analgesia, perhaps by modulating inflammatory sickle pathobiology.
Cannabinoids ameliorate mast cell activation in SCA
We recently reported that mast cell activation occurs in SCA and contributes to hyperalgesia and observed a correlative increase in dorsal skin blood flow with neurogenic inflammation and mast cell activation. showed that mast cell activation contributes to inflammation in sickle mice by enhancing the release of several cytokines or chemokines. 3 We observed that CP55,940 treatment of sickle mice for 3 weeks significantly decreased the cytokines released from skin biopsies (IL-1α, IL-6, TNFα, MCP-1; p < 0.01) compared to vehicle treatment ( Figure   2H ). Consistent with decreased mast cell activation, treatment with CP55,940 lowered the levels of GM-CSF and RANTES, two chemokines involved in mast cell recruitment and function 24, 25 , by at least 35% (p< 0.01). GM-CSF plays a critical role in regulating leukocyte counts that is often elevated in SCA. 26 We have previously reported leukocytosis in sickle mice and have shown a role of mast cells in this process. Figure 5C ). Serum SP level was elevated after H/R injury compared to normoxia in sickle mice (p<0.05; Figure 5D ). CP55,940 treatment decreased SP under normoxia and following H/R injury (p< 0.01; Figure 5 D-E). Following H/R, CB2R agonist significantly reduced SP levels as compared to vehicle treatment (p<0.05; Fig. 5E ). The CB1R agonist tended to decrease serum SP but it was not statistically significant.
Together, these data suggest that H/R-evoked mast cell activation leading to neuroinflammation is predominantly mediated by CB2R.
Cannabinoids reduce neurogenic inflammation
Earlier we found that mast cell activation contributes to neurogenic inflammation, in sickle mice. 3 Considering the H/R-induced mast cell activation observed above, we examined, the role of CBRs in ameliorating neurogenic inflammation. Evans blue (EB) leakage increased significantly in the skin of sickle mice following H/R incitement compared to normoxia (p<0.05; Figure 6A ). CP55,940 decreased EB leakage in sickle mice under normoxia as well as following H/R (p<0.001; Figure 6A ). 
Discussion
Pain in SCA, may be a result of vascular dysfunction, inflammation and direct neural injury, involving multiple targets. Moreover, the unique acute pain due to "crisis" in addition to chronic pain further adds to the complexity and heterogeneity as compared to severe pain in other conditions. Thus, it is not surprising that current pain management strategies are not always effective, requiring identification of therapeutic modalities acting on multiple targets peripherally and in the CNS. Cannabinoid receptors are unique targets because of their peripheral and central activity at a multicellular level.
Due to psychotropic effects of CB1R, the possibility to target CB2R devoid of psychotropic effects has gained attention. 27, 28 CB2R agonists and/or knockout mice provide compelling evidence that CB2R activation ameliorates neuropathic and inflammatory pain, and is protective against ischemia/reperfusion injury by decreasing the endothelial expression of adhesion molecules and secretion of chemokines 15, 29, 30 , and by attenuating the leukocyte adhesion to endothelium, trans-endothelial migration, and interrelated oxidative/nitrosative damage 31, 32 , all of which are consistent with the pathobiology of SCA. We show that targeting the cannabinoid receptors is effective in reducing inflammation, mast cell activation and neurogenic inflammation, which orchestrate pain.
Sickle mice exhibit spontaneous musculoskeletal pain and cutaneous hyperalgesia to mechanical, heat and cold stimuli. 4, 5 39 Mast cells are tightly controlled by endocannabinoid system in the skin thereby limiting excessive activation and maturation. Human mucosal-type mast cells use CB1R mediated signaling to limit degranulation and maturation from progenitor mast cells. 37 Mast cell activation was attenuated following CP55,940 treatment with a correlative decrease in tryptase, SP and cytokines released from the skin and in cutaneous blood flow. Significantly higher acetylcholine-induced forearm blood flow has been reported in sickle patients as compared to normal subjects, and significantly increased blood flow was observed in females as compared to male sickle patients. 40 Sickle females were responsive to blood flow inhibition with nitric oxide synthase inhibitor, NG-monomethyl-L-arginine, but sickle males were not, suggestive of genderbased nitric oxide-dependent and -independent mechanisms involved. Since, CP55,940 inhibited blood flow in male mice in our study, it may be acting via NO-independent mechanisms, but may also inhibit NO-dependent blood flow in females, which requires further examination.
associated with mast cell activation were also reduced in H/R incited sickle mice following CP55,940 treatment. GM-CSF and WBC counts are elevated in SCA patients 26 and in sickle mice, which are further exaggerated upon H/R incitement. 3 Our finding that CP55,940 decreased GM-CSF levels, WBC counts and also the sickle RBCs, has important implications for improving VOC and the accompanying pain. Direct effect of CP55,940 on ameliorating sickling of RBCs is an exciting possibility, but it could also be due to an indirect effect, which warrant further examination. Importantly, the observed inhibitory effect of both CB1R and CB2R agonists on neurogenic inflammation, mast cell activation, suggests the beneficial effect of cannabinoids on complex inflammatory and vascular sickle pathobiology and associated conditions.
Several studies support the analgesic effect of cannabinoids in humans. 42, 43 Sativex, a cannabis derived oromucosal spray, containing equal proportions of THC and cannabidiol has shown to be effective in treating symptoms of multiple sclerosis, including spasticity and neuropathic pain. 44, 45 Sativex is also in two phase three trials for cancer pain and neuropathic pain. 46 Furthermore, Abrams 47 showed that using vaporized cannabis in conjunction with opioids augments the analgesic effects of opioids. Unfortunately, side effects associated with higher doses such as sedation, 51 Therefore, the effect of cannabinoids on neuropsychiatric conditions in SCA requires consideration.
Interestingly we did not see an increase in hyperalgesia with the deletion of CB2R in either control or sickle mice. Earlier studies in the CB2R deleted C57BL/6 mice did not show an effect on baseline hyperalgesia as compared to wild type C57BL/6 in PWL to heat or mechanical allodynia using von Frey filaments or in tail withdrawal assay. 28, 52 In this study on CB2R -/-mice, an effect on morphine-induced antinociception was observed only in the early inflammatory phase of formalin-induced nociception, which diminished later (after 60 min). Similarly, we observed an increase in PWL in control CB2R -/-, following CP55,940 treatment which could be due to an increase in inflammation in CB2R -/-and may demonstrate an anti-inflammatory effect of CP55,940 perhaps via CB1R. An increase in grip force in control mice occurred following CP55,940 treatment but not in the control CB2R -/-, suggesting that CB2R is required for ameliorating deep hyperalgesia. Similar to our observations of no effect of CP55,940 on mechanical hyperalgesia but an increase in heat PWL in control CB2R -/-mice, in a previous study WIN 55,212-2 did not influence mechanical hyperalgesia but led to an increase in PWL-heat in CB2R -/-C57BL/6 mice in a model of neuropathic pain 28 . These data suggest a role of CB2R in the antiallodyanic effect in a neuropathic pain model. In the sickle mice we observed a uniform effect of CP55,940 on deep tissue, mechanical
and thermal hyperalgesia. This shows the diverse pathobiology of sickle pain perhaps comprised of inflammation and neuropathy, which would require both CB1R and CB2R
agonists for analgesia.
CB1R-mediated psychotropic effects and utilization of smoked Cannabis are major deterrants in the use of Cannabis as medicine. 53 However, recent discovery of CBRspecific agonists and delivery following vaporization provide an advantage to use cannabinoids in the medical setting following well-controlled clinical trials. 47 Societal stigma against "marijuana" also calls for the development of Cannabis derived medications in user-friendly drug-delivery systems to dignify their use. Evidence-based knowledge for Cannabis-derived medications, their dosage and side-effects need to be determined in disease-specific pre-clinical and clinical investigations, as emphasized recently. 53, 54 It is noteworthy, that in the states where medical Cannabis has been legalized in the United States, mean annual opioid overdose mortality rates between 1999 and 2010 were reduced by 24.8% (95% CI, -37.5% to -9.5%; P = 0.003). 55 Pain is associated with poor quality of life and increased morbidity in SCA and opioids remain the mainstay of therapy. 1 Therefore, our observations in a pre-clinical setting of SCA provide a compelling rationale to examine the potential of CBR-specific agonists and cannabinoids to treat pain and ameliorate associated pathobiology in SCA. Table S1 for summary of F (DFn, DFd)). Each value is the mean ± SEM from 5 male mice (~5 month old). and each value is the mean ± SEM from 5 male mice, ~5 month old.
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Methods
Animals
Mice were bred in AAALAC-approved housing at the University of Minnesota and as Mice were bred and phenotyped for sickle and normal human hemoglobin by IEF. respectively. All sickle and control mice CB2R -/-or CB2R +/+ were also genotyped and phenotyped for the different haemoglobins as described above.
Pain-related behaviors
Mice were acclimatized to each test protocol in a quiet room at constant temperature and tested for thermal-(heat and cold), mechanical-, and deep tissue-hyperalgesia (grip force), and catalepsy (Bar test) as described. Grip force: To assess deep tissue hyperalgesia, peak forepaw grip force was measured using a computerized grip force meter (SA Maier Co., Milwaukee, WI, USA). Mice held by the tail were made to pull on a wire-mesh gauge with their forepaws. As they were gradually pulled by the tail, the peak force (in g) exerted was recorded. Deep tissue hyperalgesia was defined as a decrease in the grip force.
Bar test: Mice were placed with their forepaws on a horizontal metal bar that was kept parallel and 5 cm above the counter-top where the hind-paws rested. The time (in seconds) spent in this position was recorded. Catalepsy was defined as an increase in the time spent in this position.
Neurogenic inflammation
Dorsal skin of mice was shaved 24 hrs before plasma extravasation was assessed using Miles assay 5 . Evans blue dye (Sigma-Aldrich, St. Louis, MO, USA) at a concentration of 50 mg/kg was injected intravenously into the tail vein 5 minutes before 50 µL of vehicle (10% ethanol, 7.5% Tween 80 in Saline), capsaicin (1.6%), or substance P (100 nM)
were injected intradermally to the dorsal skin. Each site was randomized and spaced approximately 20 mm apart. Mice were euthanized 30 minutes after intradermal injections. Blue lesions at application sites were measured for diameter and excised.
Skins were weighed, incubated in formamide for 24h at 56°C, and Evans blue content was measured spectrophotometrically at 620 nm. 
Cytokine and neuropeptide release
At study endpoint, skin punch biopsies (4 mm) were incubated in DMEM plus antibiotics with 2 mM L-glutamine and 10 mM HEPES for indicated times at 37°C in a 5% CO 2 chamber. The culture medium was analyzed for cytokines and neuropeptides. Table S1 .
Results of ANOVA analysis of the significance of cannabinoid receptor agonist modulation of the behavior of sickle mice. n/a n/a F 3, 16 = 33.77, p < 0.0001 4H n/a n/a F 3, 144 =, p < 0.0001 5B n/a n/a F 5, 24 = 7.157, p = 0.0003 5C n/a F 4, 36 = 0.6644, p = 0.6208 F 9, 36 = 13.58, p < 0.0001 5D n/a n/a F 3, 16 = 20.71, p < 0.0001 5E n/a n/a Comparisons of comparisons of baseline levels with levels at other time points and vehicle against cannabinoid receptor agonist at individual time points or multiple parameters analyzed were based on a 2-way ANOVA with Bonferroni's multiple comparisons. (Fig 1-3, Fig 4A, Fig 5C and Fig 6A-B) . A 1-way ANOVA is used to determine the effect of treatment between groups for a single parameter (Fig 4D, and Fig 5B,D,E) . p < 0.05 was considered significant, p < 0.01 was considered very significant and p < 0.0001 was considered extremely significant.
